Change in multiple sclerosis prevalence over time in Australia 2010–2017 utilising disease-modifying therapy prescription data

Campbell, Julie A.; Simpson, Steve; Ahmad, Habibah; Taylor, Bruce; Mei, Ingrid van der; Palmer, Andrew J.

doi:10.1177/1352458519861270

Cited by 46 publications

(35 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The United States validated a case-ascertainment algorithm and reported an almost doubling of prevalent cases to 913,925 in 2019. 5 An increasing prevalence of MS has also been reported across the Middle East and North African region, 6 in the Russian Federation, 7 Canada, 8 Australia 9 and in several European countries (Denmark, Germany, Poland, the United Kingdom). The Global Burden of Disease (GBD) 2016 Multiple Sclerosis Collaborators similarly reported that the prevalence of MS had risen between 1990 and 2016, estimating that there were 2,221,188 (95% Uncertainty Interval 2,033,866–2,436,858) persons living with MS in 2016.…”

Section: Resultsmentioning

confidence: 99%

Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background: High-quality epidemiologic data worldwide are needed to improve our understanding of disease risk, support health policy to meet the diverse needs of people with multiple sclerosis (MS) and support advocacy efforts. Objectives: The Atlas of MS is an open-source global compendium of data regarding the epidemiology of MS and the availability of resources for people with MS reported at country, regional and global levels. Methods: Country representatives reported epidemiologic data and their sources via survey between September 2019 and March 2020, covering prevalence and incidence in males, females and children, and age and MS type at diagnosis. Regional analyses and comparisons with 2013 data were conducted. Results: A total of 2.8 million people are estimated to live with MS worldwide (35.9 per 100,000 population). MS prevalence has increased in every world region since 2013 but gaps in prevalence estimates persist. The pooled incidence rate across 75 reporting countries is 2.1 per 100,000 persons/year, and the mean age of diagnosis is 32 years. Females are twice as likely to live with MS as males. Conclusions: The global prevalence of MS has risen since 2013, but good surveillance data is not universal. Action is needed by multiple stakeholders to close knowledge gaps.

show abstract

Section: Resultsmentioning

confidence: 99%

Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Lastly, given we did not have individual level data of the 2014-15 NHS, we were not able to exclude PwMS in the 2014-15 NHS. However, it would have only included approximately 20 people with MS out of the 19,259 NHS participants, based on 2017 MS prevalence estimates [50].…”

Section: Discussionmentioning

confidence: 99%

Change and onset-type differences in the prevalence of comorbidities in people with multiple sclerosis

Taylor

Winzenberg

et al. 2020

J Neurol

Self Cite

View full text Add to dashboard Cite

Background:Little is known about the change in prevalence of comorbidities during the disease course of people with multiple sclerosis (MS) and whether the prevalences vary by MS onset-type.Objective: To calculate the change in prevalence of comorbidities between symptom onset and the time of study, to compare the prevalences of comorbidities with those in the Australian population at the time of study and to examine onset-type differences.Methods: Comorbidity data from 1,518 participants of the Australian MS Longitudinal Study and Australian population comparator data (2014-15 National Health Survey) were used. The change in prevalence between time points and prevalence ratios (PR) at the time of study (crude, age-and-sex adjusted, and stratified by onset-type) were calculated.Results: Comorbidities were common, and those with the largest increases in prevalence between MS symptom onset and the time of study were depression (+26.9%), anxiety (+23.1%), hypertension (+21.9%), elevated cholesterol (+16.3%), osteoarthritis (+17.1%), eye diseases (+11.6%), osteoporosis (+10.9%) and cancer (+10.3%). Compared to the general population and after age-and-sex adjustment, participants had a significantly higher prevalence for 14/19 comorbidities at the time of study. The associations were strongest for anaemia, cancer (both PR>4.00), anxiety, depression, migraine (all PR>3.00), psoriasis and epilepsy (both PR>2.00). No significant differences were seen by onset-type. Conclusion:Comorbidities are common at MS symptom onset and increase with MS duration.Having MS may thus contribute to accrual of comorbidities. This emphasises the importance of optimal screening for and management of comorbidities in early MS and throughout the disease course.

show abstract

“…There is also evidence to suggest that the prevalence of multiple sclerosis in Victoria is increasing and that there is a high incidence of inflammatory bowel disease in Geelong, Victoria, among the highest reported in the international literature . Therefore, it is also plausible that vitamin D or another environmental factor is playing a role in the rates of other autoimmune diseases in Victoria.…”

Section: Discussionmentioning

confidence: 99%

Increasing prevalence of primary biliary cholangitis in Victoria, Australia

French

Mei

Simpson

et al. 2019

J of Gastro and Hepatol

Self Cite

View full text Add to dashboard Cite

Background and Aim The prevalence of primary biliary cholangitis (PBC) reported in different countries varies significantly and in some parts of the world appears to be increasing. The aim of this study was to determine the 2013 prevalence of PBC in Victoria, Australia, and to determine the time trend by comparing it with previous studies undertaken in 1991 and 2002. Methods Four case‐finding methods were used to identify cases of PBC in Victoria: (1) physicians' survey; (2) tertiary hospital search; (3) liver transplant database search; and (4) private pathology antimitochondrial antibody search. Results The prevalence of PBC in Victoria, Australia, is 189.0 per million using all four methods. The average annual increase in prevalence from 1991 to 2013 was 7.7 per million per year. Using the same case‐finding methods as the 1991 Victorian prevalence study (methods 1 and 2), the prevalence of PBC increased from 19.1 per million in 1991 to 49.4 per million in 2002 (P < 0.001) and to 80.7 per million in 2013 (P < 0.001). Conclusions The current prevalence of PBC in Victoria is significantly higher than previously reported. The use of private pathology‐based case‐finding methods is important in identifying the maximum number of PBC cases.

show abstract

Change in multiple sclerosis prevalence over time in Australia 2010–2017 utilising disease-modifying therapy prescription data

Cited by 46 publications

References 23 publications

Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition

Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition

Change and onset-type differences in the prevalence of comorbidities in people with multiple sclerosis

Increasing prevalence of primary biliary cholangitis in Victoria, Australia

Contact Info

Product

Resources

About